Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-008
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Chalazion, Dry Eye Syndromes
Interventions
LipiFlow System
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Boston, Massachusetts • Winchester, Massachusetts
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wantagh, New York
Completed Phase 2 Interventional

Phase 2b Controlled Study

NCT07140380
Conditions
Dry Eye Disease
Interventions
IVW-1001 Ophthalmic Eyelid Wipe
Drug
Lead sponsor
IVIEW Therapeutics Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Newport Beach, California
Not listed Not applicable Interventional Accepts healthy volunteers

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276
Conditions
MGD-Meibomian Gland Dysfunction
Interventions
Thermal Vectored Pulsation
Device
Lead sponsor
Dunes Eye Consultants
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dakota Dunes, South Dakota
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Conditions
Trichiasis
Interventions
azithromycin, topical tetracycline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Eye Disease, Melanoma
Interventions
Sentinel Lymph Node Mapping and Biopsy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2023
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Accepts healthy volunteers

Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

NCT05945615
Conditions
Blepharoptosis, Synkinesis, Hyperkinesis, Facial Paralysis
Interventions
Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Eyelid Diseases, Eyelid Movement Disorders, Dry Eye, Dry Eye Syndromes, Skin Laxity
Interventions
TriLift device
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Blepharitis, Conjunctivitis, Corneal Disease, Dacryoadenitis, Dacryocystitis, Keratitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Interventions
XOPH5 Ointment, Placebo
Drug
Lead sponsor
Topokine Therapeutics, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Conditions
Blepharospasm, Dystonia, Spasm
Interventions
Mexiletine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye

NCT00832130
Conditions
Chalazion, Dry Eye Syndromes
Interventions
Manual Mini System, iHeat Portable Warm Compress Therapy
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
Fayetteville, Arkansas • Morrow, Georgia • Highland Park, Illinois + 8 more
Terminated Phase 2 Interventional Results available

Acetyl Hexapeptide-8 for Blepharospasm

NCT01750346
Conditions
Focal Dystonia
Interventions
Topical acetyl hexapeptide-8, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Brain Changes in Blepharospasm

NCT00500799
Conditions
Blepharospasm
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Lipiflow vs iLux Patient Acceptance and Comfort Study

NCT04454983
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Lipiflow Thermal Pulsation System, iLux System
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Bupivacaine Epiphora Trial

NCT03266081
Conditions
Epiphora, Ptosis
Interventions
0.75% bupivacaine
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Chalazion
Interventions
OptiLIGHT
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
New York, New York • Seattle, Washington